Alpha Tau Medical Ltd

NASDAQ DRTS

Data sourced from

and

Download Data

Alpha Tau Medical Ltd Research and Development (R&D) Expense Ratio for the year ending December 31, 2023

Alpha Tau Medical Ltd Research and Development (R&D) Expense Ratio is NA for the year ending December 31, 2023. The RD expense ratio measures the proportion of a company's research and development (R&D) expenses to its revenue. It is calculated by dividing the R&D expenses by the revenue. This ratio indicates the level of investment in R&D relative to the company's revenue generation. A higher ratio suggests a greater allocation of resources towards research and development activities, indicating a focus on innovation and potential future growth.

NASDAQ: DRTS

Alpha Tau Medical Ltd

CEO	Mr. Uzi Sofer
IPO Date	March 8, 2021
Location	Israel
Headquarters	5 Kiryat Hamada Street, Jerusalem, Israel, 9777605
Employees	121
Sector	Healthcare
Industry	Biotechnology

Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Key trends